More about
Hpv-Negative Cancer
News
June 27, 2023
4 min read
Save
Combination exhibits ‘impressive’ activity in HPV-negative head and neck cancer
The combination of ficlatuzumab and cetuximab extended PFS for patients with pan-refractory recurrent or metastatic head and neck squamous cell carcinoma, according to randomized phase 2 study results.